SINOVAC BIOTECH LTD's ticker is SVA and the CUSIP is P8696W104. A total of 28 filers reported holding SINOVAC BIOTECH LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,666 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q2 2023 | $2,666 | -90.1% | 412 | 0.0% | 0.00% | – |
| Q3 2022 | $27,000 | +800.0% | 412 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | – | 412 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 412 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 412 | 0.0% | 0.00% | – |
| Q2 2021 | $3,000 | -88.9% | 412 | 0.0% | 0.00% | – |
| Q1 2021 | $27,000 | +800.0% | 412 | 0.0% | 0.00% | – |
| Q4 2020 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q3 2020 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q4 2019 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q3 2019 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q2 2019 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q1 2019 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 412 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | -75.0% | 412 | -71.2% | 0.00% | – |
| Q1 2018 | $12,000 | -94.5% | 1,432 | -94.8% | 0.00% | -100.0% |
| Q4 2017 | $217,000 | -1.4% | 27,490 | -12.1% | 0.00% | 0.0% |
| Q3 2017 | $220,000 | +5.8% | 31,261 | +1.3% | 0.00% | 0.0% |
| Q2 2017 | $208,000 | +1980.0% | 30,861 | +1621.2% | 0.00% | – |
| Q1 2017 | $10,000 | -60.0% | 1,793 | -58.2% | 0.00% | – |
| Q4 2016 | $25,000 | – | 4,293 | +47600.0% | 0.00% | – |
| Q4 2015 | $0 | -100.0% | 9 | -97.0% | 0.00% | – |
| Q3 2015 | $2,000 | 0.0% | 302 | 0.0% | 0.00% | – |
| Q2 2015 | $2,000 | -97.0% | 302 | -97.8% | 0.00% | -100.0% |
| Q1 2015 | $67,000 | -14.1% | 13,566 | -9.1% | 0.00% | 0.0% |
| Q4 2014 | $78,000 | +143.8% | 14,927 | +123.0% | 0.00% | – |
| Q3 2014 | $32,000 | -73.8% | 6,695 | -69.0% | 0.00% | -100.0% |
| Q2 2014 | $122,000 | -33.0% | 21,591 | -14.5% | 0.00% | -33.3% |
| Q1 2014 | $182,000 | +4450.0% | 25,252 | +3340.3% | 0.00% | – |
| Q4 2013 | $4,000 | -55.6% | 734 | -52.9% | 0.00% | – |
| Q3 2013 | $9,000 | -55.0% | 1,559 | -68.9% | 0.00% | – |
| Q2 2013 | $20,000 | – | 5,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,718,735 | $340,500,000 | 6.32% |
| Vivo Capital, LLC | 5,900,000 | $38,173,000 | 4.21% |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2,042 | 0.72% |
| Yorktown Management & Research Co Inc | 74,893 | $485,000 | 0.63% |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $259,000 | 0.00% |
| Renaissance Technologies | 2,375,841 | $1,537,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 1,687 | $11,000 | 0.00% |
| NORTHERN TRUST CORP | 13,787 | $55,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 412 | $27,000 | 0.00% |